The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Long-term outcomes of VRD, auto-HCT with Mel200 conditioning & lenalidomide maintenance in MM
Mahmoud Gaballa, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a retrospective analysis evaluating long-term outcomes of patients with multiple myeloma treated with VRD induction (bortezomib, lenalidomide, and dexamethasone), followed by autologous hematopoietic stem cell transplantation (auto-HCT) with melphalan 200mg/m2 (Mel200) conditioning and lenalidomide maintenance. This regimen is found to be associated with very good outcomes in patients with multiple myeloma, especially those with standard-risk cytogenetics and complete response as their best final response. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
